IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No. Unassigned

Confirmation No. Unassigned

Applicant

Wing CHEUNG et al.

Filed

24 March 2004

TC/Art Unit

Unassigned

Examiner

Unassigned

Docket No.

38081-00036

Customer No.

23767

INFORMATION DISCLOSURE STATEMENT **UNDER 37 C.F.R. § 1.56(b)**

Mail Stop Patent Application Commissioner for Patents Alexandria, VA 22313-1450

Sir:

In order to comply with Applicants' duty of disclosure pursuant to 37 C.F.R. §1.56, submitted herewith on Form PTO/SB/08A is a listing of documents known to Applicants. The submission of any document herewith, which is not a statutory bar, is not intended as an admission that such document constitutes prior art against the claims of the present application or is considered to be material to patentability as defined in 37 C.F.R. § 1.56(b). Applicants do not waive any rights to take any action which would be appropriate to antedate or otherwise remove as a competent reference any document which is determined to be a prima facie prior art reference against the claims of the present application.

Applicants submit herewith on Form PTO/SB/08A a list of the documents cited by or submitted to the Patent Office in parent application Serial No. 09/569,612, filed on 10 May 2000.

Atty. Docket No. 38081-00036

As provided in 37 C.F.R. 1.98(d), copies of the documents are not being provided since they were previously cited by or submitted to the Patent Office in parent application Serial No. 09/569,612, filed on 10 May 2000.

Applicants respectfully request that the listed documents be considered by the Examiner and be made of record in the present application and that an initialed copy of Form PTO/SB/08A be returned in accordance with M.P.E.P. § 609.

This statement is being filed in compliance with 37 CFR §1.97(b), within three (3) month of the filing date of the application. Accordingly, no fee is required in connection with this filing. Nonetheless, the Commissioner is hereby authorized to charge any deficiency or credit any overpayment associated with the filing of this paper to undersigned's Deposit Account No. 50-1067.

Respectfully submitted,

24 March 2004

Don J. Pelto Reg. No. 33,754

Preston Gates Ellis & Rouvelas Meeds LLP 1735 New York Avenue NW, Suite 500 Washington, DC 20006 Tel. 202.628.1700

Fax. 202.331.1024

Approved for use through 10/31/2002.OMB 0651-0031

U. S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Sub	ostitute for form 1449A/PTO			Complete if Known		
				Application Number	Unassigned	
11	VFORMATION	1 DI	SCLOSURE	Filing Date	24 March 2004	
8	STATEMENT B	3Y A	APPLICANT	First Named Inventor	Wing CHEUNG et al.	
				Art Unit	Unassigned	
	(use as many she	eets as	necessary)	Examiner Name	Unassigned	
Sheet	1	of	2	Attorney Docket Number	38081-00036	

			U.S. PA	TENT DOCUMENTS		
Cuaminas	C:4-	Document Number	Publication Date	Name of Detentos or Applicant	Pages, Columns, Lines,	
Examiner Initials*	Cite No.1	Number-Kind Code ² (if known)	MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Where Relevant Passages or Relevant Figures Appear	
	A1	4,732,889	03/1988	CYNSHI et al.		
	A2	4,748,600	05/1988	URQUHART	***	
	A3	5,354,934	10/1994	PITT et al.		
	A4	5,4169,071	05/1995	IGARI et al.		
	A5	5,541,158	07/1996	VANCE et al.		
	A6	5,674,534	10/1997	ZALE et al.		
	A7	5,739,277	04/1998	PRESTA et al.		
	<u> </u>					

		FOREI	GN PATENT D	OCUMENTS		
		Foreign Patent Document	Publication Date	Name of Patentee or	Pages, Columns, Lines.	
Examiner Initials*	Cite No. ¹	Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	MM-DD-YYYY	Applicant of Cited Document	Where Relevant Passages or Relevant Figures Appear	T ⁶
	A8	JP 2-96535	04/1990			1
L	<u> </u>					

Applicant's unique citation designation number (optional). ² See attached Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the application number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

		OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title-of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	A9	SALMONSON, T., "Pharmacokinetic and Pharmacodynamic Studies on Recombinant Human Erythropoietin," J. Uro. Nephrol. Suppl. 1990 0(129), pp 1-66 (Abstract) BIOSIS No. 1990:497818	
•		MATSUSHIA, et al., "A computer program (PPMODELS) with NeXTSTEP for calculating distribution of drugs based on physiological pharmacokinetic model," Sch. Med., Kanazawa Univ 1996 22(2) pp 123-132 (Abstract)	
	A11	PHYSICIANS DESK REFERENCE, 51 st ed. (1997) pp 489-495 Medical Economics Company, Inc., Montvale, NJ.	
	A12	WICHMANN, et al., "A mathematical model of erythropoiesis in mice and rats," Cell Tissue Kinet, (1989) 22(1) pp 31-49.	
	A13	COLBURN et al., "Pharmacokinetic Analysis of Drug Concentration Data Obtained during Repetitive Drug Administration," <i>J. Pharmaceutical Sci.</i> (1977) 66(4) 66 530-533	
	A14	WALTON, et al., "Computer support for determining drug dose systematic review and meta- analysis," Brit. Medical Journal (1999) 318 pp 984-990	
	A15	McMAHON, et al., "Pharmackinetic and effects of recombinant human erythropoietin after intravenous and subcutaneous injections in healthy volunteers," <i>Blood</i> (1990) 76(9) pp 1718-1722	
			T^{-}

Examiner	Date
Signature	Considered

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Approved for use through 10/31/2002.0MB 0651-0031
U. S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Sul	bstitute for form 1449A/PTO	,		Complete if Known			
				Application Number	Unassigned		
11	NFORMATION	1 DI:	SCLOSURE	Filing Date	24 March 2004		
5	STATEMENT E	BY /	APPLICANT	First Named Inventor	Wing CHEUNG et al.		
				Art Unit	Unassigned		
	(use as many she	eets as	necessary)	Examiner Name	Unassigned		
Sheet	2	of	2	Attorney Docket Number	38081-00036		

U.S. PATENT DOCUMENTS						
Cito	Document Number	Publication Date	Name of Patentee or Applicant	Pages, Columns, Lines, Where Relevant		
No.1	Number-Kind Code ² (if known)	MM-DD-YYYY	of Cited Document	Passages or Relevant Figures Appear		
				· · · · · · · · · · · · · · · · · · ·		
	Cite No.¹	Cite	Cite Document Number Publication Date	Cite Document Number Publication Date Name of Patentee or Applicant		

		FOREI	GN PATENT	DOCUMENTS		
		Foreign Patent Document	Publication Date	Name of Patentee or	Pages, Columns, Lines,	
Examiner Initials*	Cite No. ¹	Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	MM-DD-YYYY	Applicant of Cited Document	Where Relevant Passages or Relevant Figures Appear	Te
					11.7	
						\Box

Applicant's unique citation designation number (optional). ² See attached Kinds Codes of USPTO Patent Documents at www.uspto.qov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the application number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Cite No.1 Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, page(s), volume-issue number(s), publisher, city and/or country where published. A16 HU, et al., "Comparison of Some Control Strategies for Three-Compartment PK/PD Models," J. of Pharmacokinetics and Biopharmaceutics, Biopharmaceutics 1994 22(6) pp 525-550 A17 GOBBURU, "Role of dosage regimen in controlling indirect pharmacodynamic responses," Adv.	f
Pharmacokinetics and Biopharmaceutics, Biopharmaceutics 1994 22(6) pp 525-550	
A17 GOBBURU "Role of dosage regimen in controlling indirect pharmacodynamic responses." Adv	
Drug Delivery Reviews, (1998) 33 pp 221-233	
A18 PORT, R.E. et al., "Predicting the time course of hemoglobin in children treated with erythropoiet for renal anemia," <i>Br. J. Clin. Pharmacol</i> (1998) 46(5) pp 461-466	n
	+
	+
L	Drug Delivery Reviews, (1998) 33 pp 221-233 18 PORT, R.E. et al., "Predicting the time course of hemoglobin in children treated with erythropoieti

Examiner	Date	,440)
Signature	Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.